The stock price of point-of-care drug and disease reference vendor Epocrates Inc. fell more than 7 percent in morning trading on Feb. 29 after the company announced mixed financial results and the intent to sell its newly developed electronic health record system.

The San Mateo, Calif.-based company acknowledged that building the EHR has hindered its ability to pursue other ways to expand its portfolio. “As a result, we are exploring strategic alternatives for our EHR offering,” according to a statement. The company noted it needed to focus more “on the natural extension of our core business.”

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access